肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CLIN CANCER RES：巨噬细胞通过改变VEGFR表达促进抗VEGF治疗耐药

2017-11-26 MedSci MedSci原创

抗VEGF巨噬细胞耐药
关注

VEGF靶向治疗在肿瘤患者中具有一定疗效，但获得性耐药很常见。对其耐药机制的理解现在尚不明确。CLIN CANCER RES近期发表了一篇文章，研究了这一问题。

VEGF靶向治疗在肿瘤患者中具有一定疗效，但获得性耐药很常见。对其耐药机制的理解现在尚不明确。CLIN CANCER RES近期发表了一篇文章，研究了这一问题。

作者建立了抗VEGF治疗获得性耐药的模型来研究免疫细胞在VEGF阻滞获得性耐药发展过程中所扮演的角色。在体内和体外研究中探索巨噬细胞在耐药中所发挥的作用。使用抗VEGF抗体获得性耐药鼠肿瘤模型，作者发现了巨噬细胞在这类耐药中具有之前未知的作用。巨噬细胞会招募到肿瘤微环境中且与抗VEGF抗体获得性耐药发生有关。清除耐药后出现的巨噬细胞可以抑制肿瘤生长并延长荷瘤小鼠的生存。在巨噬细胞缺陷鼠模型中，抗VEGF抗体获得性耐药无法出现，但是注射巨噬细胞后可以诱导产生抗VEGF抗体获得性耐药。下调巨噬细胞VEGFR-1和VEGFR-3表达会伴随血管生成通路上调，有助于抗VEGF治疗逃逸。

文章最后认为，这些发现为目前的抗血管生成治疗疗效不显着的原因提供了新的理解，为使用联合疗法治疗卵巢癌及其他肿瘤的提供了新的机会。

原始出处：
Heather J.Dalton,Sunila Pradeep,et al.Marophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression.CLIN CANCER RES.November 2017 doi:10.1158/1078-0432.CCR-17-0647

本文系梅斯医学（MedSci）原创编译整理，转载需授权！


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=265950, encodeId=01ad2659502f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/f599c0dc68895bdd7ee58a414e0a3c85.jpg, createdBy=9f9b1569485, createdName=liuyicheng1981, createdTime=Fri Dec 01 12:44:26 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368492, encodeId=98c2136849249, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Tue Nov 28 01:02:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407290, encodeId=07a4140e2907c, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18347, encryptionId=d5b01834e3a, topicName=VEGFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8d2627959, createdName=jml2010, createdTime=Tue Nov 28 01:02:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534356, encodeId=b0f415343567d, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Tue Nov 28 01:02:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621232, encodeId=901b162123220, content=<a href='/topic/show?id=395f5514e6d' target=_blank style='color:#2F92EE;'>#抗VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55147, encryptionId=395f5514e6d, topicName=抗VEGF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e44a20222078, createdName=d830379, createdTime=Tue Nov 28 01:02:00 CST 2017, time=2017-11-28, status=1, ipAttribution=)]
    2017-12-01 liuyicheng1981

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=265950, encodeId=01ad2659502f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/f599c0dc68895bdd7ee58a414e0a3c85.jpg, createdBy=9f9b1569485, createdName=liuyicheng1981, createdTime=Fri Dec 01 12:44:26 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368492, encodeId=98c2136849249, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Tue Nov 28 01:02:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407290, encodeId=07a4140e2907c, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18347, encryptionId=d5b01834e3a, topicName=VEGFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8d2627959, createdName=jml2010, createdTime=Tue Nov 28 01:02:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534356, encodeId=b0f415343567d, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Tue Nov 28 01:02:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621232, encodeId=901b162123220, content=<a href='/topic/show?id=395f5514e6d' target=_blank style='color:#2F92EE;'>#抗VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55147, encryptionId=395f5514e6d, topicName=抗VEGF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e44a20222078, createdName=d830379, createdTime=Tue Nov 28 01:02:00 CST 2017, time=2017-11-28, status=1, ipAttribution=)]
    2017-11-28 fanweitanzhen

    #VEGF#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=265950, encodeId=01ad2659502f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/f599c0dc68895bdd7ee58a414e0a3c85.jpg, createdBy=9f9b1569485, createdName=liuyicheng1981, createdTime=Fri Dec 01 12:44:26 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368492, encodeId=98c2136849249, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Tue Nov 28 01:02:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407290, encodeId=07a4140e2907c, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18347, encryptionId=d5b01834e3a, topicName=VEGFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8d2627959, createdName=jml2010, createdTime=Tue Nov 28 01:02:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534356, encodeId=b0f415343567d, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Tue Nov 28 01:02:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621232, encodeId=901b162123220, content=<a href='/topic/show?id=395f5514e6d' target=_blank style='color:#2F92EE;'>#抗VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55147, encryptionId=395f5514e6d, topicName=抗VEGF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e44a20222078, createdName=d830379, createdTime=Tue Nov 28 01:02:00 CST 2017, time=2017-11-28, status=1, ipAttribution=)]
    2017-11-28 jml2010

    #VEGFR#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=265950, encodeId=01ad2659502f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/f599c0dc68895bdd7ee58a414e0a3c85.jpg, createdBy=9f9b1569485, createdName=liuyicheng1981, createdTime=Fri Dec 01 12:44:26 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368492, encodeId=98c2136849249, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Tue Nov 28 01:02:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407290, encodeId=07a4140e2907c, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18347, encryptionId=d5b01834e3a, topicName=VEGFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8d2627959, createdName=jml2010, createdTime=Tue Nov 28 01:02:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534356, encodeId=b0f415343567d, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Tue Nov 28 01:02:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621232, encodeId=901b162123220, content=<a href='/topic/show?id=395f5514e6d' target=_blank style='color:#2F92EE;'>#抗VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55147, encryptionId=395f5514e6d, topicName=抗VEGF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e44a20222078, createdName=d830379, createdTime=Tue Nov 28 01:02:00 CST 2017, time=2017-11-28, status=1, ipAttribution=)]
    2017-11-28 liuyiping

    #GFR#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=265950, encodeId=01ad2659502f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/f599c0dc68895bdd7ee58a414e0a3c85.jpg, createdBy=9f9b1569485, createdName=liuyicheng1981, createdTime=Fri Dec 01 12:44:26 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368492, encodeId=98c2136849249, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Tue Nov 28 01:02:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407290, encodeId=07a4140e2907c, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18347, encryptionId=d5b01834e3a, topicName=VEGFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8d2627959, createdName=jml2010, createdTime=Tue Nov 28 01:02:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534356, encodeId=b0f415343567d, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Tue Nov 28 01:02:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621232, encodeId=901b162123220, content=<a href='/topic/show?id=395f5514e6d' target=_blank style='color:#2F92EE;'>#抗VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55147, encryptionId=395f5514e6d, topicName=抗VEGF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e44a20222078, createdName=d830379, createdTime=Tue Nov 28 01:02:00 CST 2017, time=2017-11-28, status=1, ipAttribution=)]
    2017-11-28 d830379

    #抗VEGF#

    0

相关资讯

CCC：一线靶向治疗进展期结直肠癌，抗EGFR优于抗VEGF单抗（ Meta分析）

近日，西澳大利亚大学及珀斯皇家医院的研究人员就进展期结直肠癌一线靶向治疗的随机临床试验数据进行了一项meta分析，发现进展期结直肠癌患者一线抗EGFR靶向治疗较抗VEGF治疗可获得更佳的客观有效率（ORR）和总生存期（OS），最新研究成果在线发表于1月8日的Clincal Colorectal Cancer杂志上。